BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16791761)

  • 1. Hematologic disorders in critically ill patients.
    Mercer KW; Gail Macik B; Williams ME
    Semin Respir Crit Care Med; 2006 Jun; 27(3):286-96. PubMed ID: 16791761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.
    Drews RE
    Clin Chest Med; 2003 Dec; 24(4):607-22. PubMed ID: 14710693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials.
    Caldwell SH; Chang C; Macik BG
    Hepatology; 2004 Mar; 39(3):592-8. PubMed ID: 14999675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
    Murkin JM
    Can J Anaesth; 2002 Dec; 49(10):S21-6. PubMed ID: 12546007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-induced thrombocytopenia.
    Warkentin TE
    Curr Opin Crit Care; 2015 Dec; 21(6):576-85. PubMed ID: 26539932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant factor VIIa in the treatment of bleeding.
    Midathada MV; Mehta P; Waner M; Fink LM
    Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review.
    Franchini M; Manzato F; Salvagno GL; Lippi G
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):589-93. PubMed ID: 17890943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Massive transfusion coagulopathy.
    Levy JH
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S59-63. PubMed ID: 16427387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma.
    Martinowitz U; Kenet G; Lubetski A; Luboshitz J; Segal E
    Can J Anaesth; 2002 Dec; 49(10):S15-20. PubMed ID: 12546003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B; Wiis J
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
    Allen GA; Hoffman M; Roberts HR; Monroe DM
    Can J Anaesth; 2002 Dec; 49(10):S7-14. PubMed ID: 12546000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant activated factor VII (rFVIIa, NovoSeven).
    Agarwal MB; Patnaik M
    J Assoc Physicians India; 2005 Aug; 53():717-20. PubMed ID: 16398083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology.
    Levi M; Toh CH; Thachil J; Watson HG
    Br J Haematol; 2009 Apr; 145(1):24-33. PubMed ID: 19222477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant activated Factor VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation.
    Fischer D; Schloesser R; Buxmann H; Veldman A
    J Pediatr Hematol Oncol; 2008 May; 30(5):337-42. PubMed ID: 18458565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
    Ragni MV
    Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-early hemostatic therapy for acute intracerebral hemorrhage.
    Mayer SA; Rincon F
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S70-6. PubMed ID: 16427389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematologic failure.
    Levi M; Schultz M
    Semin Respir Crit Care Med; 2011 Oct; 32(5):651-9. PubMed ID: 21989700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in the therapeutic use of a "so-called" universal hemostatic agent: recombinant factor VIIa.
    Hoots WK
    Hematology Am Soc Hematol Educ Program; 2006; ():426-31. PubMed ID: 17124094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.